Sentiment Analysis of the earnings transcript to help figure out if there are any bullish or bearish sentiments that could be gathered from it. We're doing ML and AI based analysis on the earnings call to get some more insights.
Please consider a small donation if you think this website provides you with relevant information
| Statement |
|---|
| So we're confident in our ability to continue to grow and scale that into a more meaningful number here over the next quarter or two |
| We have great award-winning products |
| As Sibyl will speak to more, we completed our PET clinical study and are excited about the credibility it brings to our products |
| We continue to believe the results from our clinical studies and other science provide us with a unique differentiated position for both product efficacy and education in that category |
| As Brad will explain, our adjusted EBITDA for the quarter was just a tad under $800,000 loss, resulting in an approximate $3 million improvement over prior year and $1.8 million improvement versus the December quarter |
| We see this designation critical to consumers outside of professional athletes and believe the designation continues to enhance the credibility of the cbdMD brand |
| We have stabilized our revenue and our business fundamentals continue to improve |
| And we've seen really strong adoption of that, and they're seeing great retention |
| I can say that our efforts were successful and our products are able to be sold in those markets |
| Sequentially, our non-GAAP adjusted EBITDA loss improved by $1.8 million from the December '22 quarter |
| So by reducing and pulling back some of that spend and driving the consumers into higher-value, higher-end products, we're seeing stronger retention and improved LTV rates |
| We have a fantastic base platform and with just a little growth, we expect to have a positive EBITDA business |
| Of note, among other encouraging results, our core broad spectrum blend indicated positive outcomes from mood improvement, pain reduction and reduction of inflammation in healthy adults |
| As our new team marked on our direct-to-consumer business and started to drive traffic, we saw a number of areas where we can improve on our customer experience, conversion rates and become more nimble |
| In the past, we have discussed our approach to science and laid the foundation for cbdMD to deliver superior everyday wellness products that are formulated to specifically address the needs of our customers |
| We've just sort of onboarded some incremental resources that have a really strong track record |
| So the products we launched last year have been doing tremendously well for us |
| We believe our science is second to none, and we have a strong voice in Washington |
| We believe there is an industry well-built |
| I'm pleased to inform you that our broad spectrum hemp extract positively impacted most of the outcome measures assessed using the client-specific outcome measures and the CPPI [ph] as compared to baseline measures |
| While you can see we made very strong strides to operate in a much leaner and disciplined organization, the margin of era [ph] became too small |
| Never ever been more encouraged about the resources coming together to put forward a strong response to the FDA's statements earlier in the year |
| Many of our CBD industry peers operate legitimate businesses, care about safety of consumers and understand that the industry is poised for significant growth with regulatory clearing |
| Based on the preliminary findings of that study, we know that CBD really does improve our customers' health and wellness in some key areas, and we're excited to share that data and our messaging to our customers |
| We are working to address these items and expect positive changes to our consumer experience with our online store in the coming months |
| Our results in the second quarter show that we are building the right strategic plans and the right team to deliver on results |
| This represents one of the best net performing quarters we have had as a public brand on significantly lower revenues than the prior better quarters |
| On a final note, before I turn it over to Sibyl, I'm very encouraged by some of the industry activity we are seeing |
| Maxim did a solid job in a very difficult market |
| I think that's going to help us continue to accelerate our DTC revenue and the conversion and return on metrics that comes from our marketing spend |
| Statement |
|---|
| We've seen the FDA's posture have real commercial impact and impede the growth of an industry that we believe provides real value to its customer base |
| We believe sales were impacted during the quarter by pantry loading prior to our new high-strength product launch, a pullback in marketing spend and microeconomic forces on consumers |
| Total net sales for the second quarter of fiscal '23 were $6.2 million or a 35% decrease from the prior year comparative quarter |
| So yes, so the top line came down, but your losses came down significantly |
| New product development has slowed |
| Our wholesale business generated $1.4 million of net sales for the second quarter of fiscal '23, down 56% as compared to $3 million for the comparative quarter in fiscal '22 |
| Overall, this resulted in a loss of operations of approximately $1.4 million for the second quarter of fiscal '23 as compared to $4.7 million loss for the prior year period, meaning we reduced our loss of $3.3 million over prior year on a GAAP basis |
| The capital markets are incredibly challenging at the moment, especially after the April banking crisis |
| We have previously discussed our steps to address the lack of regulatory clarity and challenging the FDA's position in refusal to regulate |
| Unfortunately, our stock came under strong pressure, and we needed to implement the reverse split to maintain compliance with the NYSE American |
| Based on April's results and our current quarter run rate, we are anticipating a continued reduction in both GAAP and our non-GAAP adjusted EBITDA loss for the third quarter |
| This lack of FDA guidance has forced states to step in, specifically to address the recent concerns of THC derivatives like Delta 8, Delta 10, CHCO and HHC, none of which are legitimate hemp-derived dietary supplements and all of which further confuse the objective of clear regulation of our products is dietary supplements |
| Our operating expenses for the second quarter of fiscal '23 totaled $5.4 million, which is down from $11.5 million in the prior year comparative quarter |
| We made hard decisions to say goodbye to many of our colleagues and friends and significantly reduced our staff |
| Revenues were impacted as we transitioned to the new SKU offering with lower wholesale price points as compared to the prior year |
| This was a 26% year-over-year quarterly decrease |
| Our current assets as of March 31, 23 decreased approximately 37% from September 30, 2022, to $10.1 million |
| Our non-GAAP adjustments to operating expenses for the second quarter of fiscal 2023 included a $118,000 in non-cash employee stock expense, $380,000 in depreciation and amortization expense and $108,000 associated with non-cash AR credits related to our marketing agreement with A360, resulting in a non-GAAP adjusted EBITDA loss of $795,000 for the second quarter of fiscal '23 as compared to a $3.6 million non-GAAP adjusted EBITDA loss in the second quarter of fiscal '22 |
| The post-split pressure continued effectively limiting on the capital cushion available under our equity line |
| Although there are still some hurdles to overcome with different regulatory requirements in different states that impact the sales of hemp-derived CBD products |
Please consider a small donation if you think this website provides you with relevant information